Premier Alternatives

ParcelBio

Drug Discovery · San Francisco, CA · Founded 2023 · Privately Held (backing)

Developer of a programmable technology designed to deliver messenger ribonucleic acid to diverse cell types in the body. ParcelBio is based in San Francisco, CA and was founded in 2023. It was valued at $41.2 million at its seed round in Mar 2026, the last priced event on record. It has raised $13.7 million across 1 recorded round; the latest was a seed round in May 2024.

PMV mark · valuation
$41.2M
Oct 2026
Priced at
its seed round
Mar 2026
Total raised
$13.7M
Last round
Seed Round
May 2024

ParcelBio key facts

as of Oct 2026
  • Developer of a programmable technology designed to deliver messenger ribonucleic acid to diverse cell types in the body.
  • ParcelBio is valued at approximately $41.2M as of Oct 2026, set at its seed round, Mar 2026; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $13.7M across 1 recorded rounds; the latest was Seed Round in May 2024.
  • Notable investors include Y Combinator, Alumni Ventures, Pioneer Fund, Metaplanet Holdings, 468 Capital — 13 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$41.2M

Valued at $41.2M at its seed round, Mar 2026. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of ParcelBio with a free account
  • ·The complete investor list: 13 names
  • ·Watch ParcelBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ParcelBio funding rounds

1 rounds
May 2024Seed Round—▮
Full funding history →

ParcelBio valuation

ParcelBio was valued at $41.2 million at its seed round in Mar 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has ParcelBio raised?

ParcelBio has raised $13.7 million in total; 1 of its rounds is on record. The most recent was a seed round in May 2024.

ParcelBio investors

13 investors are on record for ParcelBio, including Y Combinator, Alumni Ventures, Pioneer Fund and Metaplanet Holdings. By type, the record holds 9 venture capital firms. The seed round in May 2024 drew 11 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Hinge Bio ($46 million), Persephone Biosciences ($37.3 million) and Solarea Bio ($37 million).

About ParcelBio

Developer of a programmable technology designed to deliver messenger ribonucleic acid to diverse cell types in the body. The company's technology leverages technology to create ribonucleic acid therapeutics that are more targeted, potent and durable than traditional drugs, enabling medical professionals to treat diseases such as cancer, genetic disorders and infectious diseases.

Industry
Drug Discovery
Sector
Healthcare
HQ
San Francisco, CA, United States
Founded
2023
Employees
6
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.